Advertisement

GHB

  • Jonathan Henssler
  • Felix Bermpohl
Living reference work entry
Part of the Springer Reference Psychologie book series (SRP)

Zusammenfassung

γ-Hydroxy-Buttersäure (GHB) ist eine natürlich vorkommende Substanz, die sich im Gewebe von Säugetieren und in einigen Früchten findet. Seit den 1960er-Jahren wird GHB präklinisch und klinisch in der Geburtshilfe, Anästhesie sowie der Sucht- und Schlafmedizin angewendet. In pharmakologischer Dosierung wirkt GHB hemmend auf das zentrale Nervensystem.

Missbräuchlicher Konsum findet vorwiegend in den USA, Europa und Australien Verbreitung und steht in Verbindung mit rauschartigen, luststeigernden, euphorisierenden und anabolen Eigenschaften. Mit regelmäßigem Konsum zeigen sich Toleranz- und Abhängigkeitsentwicklung. Der Gebrauch von GHB im Zusammenhang mit Sexual-Delikten wurde wiederholt beschrieben.

Die individuell stark schwankende Dosis-Wirkungs-Beziehung birgt ein hohes Risiko für Intoxikationen mit schweren Nebenwirkungen. Insbesondere der häufig vorkommende Mischkonsum führt wiederholt zu letalen Komplikationen.

Besonderes Missbrauchs- und Gesundheitsgefährdungs-Potenzial besitzen die frei erhältlichen Vorläufersubstanzen γ-Butyrolacton (GBL) und 1,4-Butandiol (1,4-BD), die in der Industrie Anwendung finden.

Schlüsselwörter

GHB γ-Hydroxy-Buttersäure γ-Hydroxybutyrat GBL 1,4-BD 

Literatur

  1. Absalom, N., Eghorn, L. F., Villumsen, I. S., Karim, N., Bay, T., Olsen, J. V., … & Wellendorph, P. (2012). alpha4betadelta GABA(A) receptors are high-affinity targets for gamma-hydroxybutyric acid (GHB). Proceedings of National Academy of Sciences of the USA, 109(33), 13404–13409. doi:10.1073/pnas.1204376109.Google Scholar
  2. Andriamampandry, C., Taleb, O., Kemmel, V., Humbert, J. P., Aunis, D., & Maitre, M. (2007). Cloning and functional characterization of a gamma-hydroxybutyrate receptor identified in the human brain. FASEB Journal, 21(3), 885–895. doi:10.1096/fj.06-6509com.CrossRefPubMedGoogle Scholar
  3. Bessman, S. P., & Fishbein, W. N. (1963). Gamma-hydroxybutyrate, a normal brain metabolite. Nature, 200, 1207–1208.CrossRefPubMedGoogle Scholar
  4. Bettler, B., Kaupmann, K., Mosbacher, J., & Gassmann, M. (2004). Molecular structure and physiological functions of GABA(B) receptors. Physiological Reviews, 84(3), 835–867. doi:10.1152/physrev.00036.2003.CrossRefPubMedGoogle Scholar
  5. Brailsford, A. D., Cowan, D. A., & Kicman, A. T. (2012). Pharmacokinetic properties of gamma-hydroxybutyrate (GHB) in whole blood, serum, and urine. Journal of Analytical Toxicology, 36(2), 88–95. doi:10.1093/jat/bkr023.CrossRefPubMedGoogle Scholar
  6. Busardo, F. P., & Jones, A. W. (2015). GHB pharmacology and toxicology: Acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Current Neuropharmacology, 13(1), 47–70. doi:10.2174/1570159X13666141210215423.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Carter, L. P., Richards, B. D., Mintzer, M. Z., & Griffiths, R. R. (2006). Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology, 31(11), 2537–2551. doi:10.1038/sj.npp.1301146.CrossRefPubMedGoogle Scholar
  8. Centers for Disease Control and Prevention. (1997). Gamma hydroxy butyrate use – New York and Texas, 1995–1996. MMWR. Morbidity and Mortality Weekly Report, 46(13), 281–283.Google Scholar
  9. Chin, R. L., Sporer, K. A., Cullison, B., Dyer, J. E., & Wu, T. D. (1998). Clinical course of gamma-hydroxybutyrate overdose. Annals of Emergency Medicine, 31(6), 716–722.CrossRefGoogle Scholar
  10. Cousto, H. (2011). Fachinformation: GHB (Gamma-Hydroxybutyrat) – Mischkonsum. http://www.drogenkult.net/index.php/GHB.pdf?file=GHB&view=pdf. Zugegriffen am 15.05.2015.
  11. de Jong, C. A., Kamal, R., Dijkstra, B. A., & de Haan, H. A. (2012). Gamma-hydroxybutyrate detoxification by titration and tapering. European Addiction Research, 18(1), 40–45. doi:10.1159/000333022.CrossRefPubMedGoogle Scholar
  12. Dean, W., Joy, M., & Fowkes, S. (1998). GHB: The natural mood enhancer. Petaluma: Smart Publications.Google Scholar
  13. Dines, A. M., Wood, D. M., Yates, C., Heyerdahl, F., Hovda, K. E., Giraudon, I., . . . Dargan, P. I. (2015). Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clinical Toxicology (Phila), 53(9), 893–900. doi:10.3109/15563650.2015.1088.Google Scholar
  14. Drug Abuse Warning Network. (2006). Drug abuse warning network, 2005: National estimates of drug-related emergency department visits (DAWN Series D-29, DHHS Publication No. [SMA] 07–4256). Rockville.Google Scholar
  15. Drug Enforcement Administration (DEA). (2005). Recordkeeping and reporting requirements for drug products containing gamma-hydroxybutyric acid (GHB). Final rule. Federal Register, 70, 291.Google Scholar
  16. EMCDDA. (2008). Thematic papers – GHB and its precursor GBL: An emerging trend case study.Google Scholar
  17. EMCDDA. (2011). 2011 Annual report on the state of the drugs problem in Europe EMCDDA, Lisbon, November 2011. Lisbon.Google Scholar
  18. EMCDDA, EBDD. (2015). Europäischer Drogenbericht.Google Scholar
  19. EMCDDA (Producer). (2013, May 10, 2016). Statistical bulletin 2013 – Table SZR-21. Other substances seized, not included in other SZR tables, 2004–11. http://www.emcdda.europa.eu/stats13/szrtab21. Zugegriffen am 15.05.2015.
  20. Expert Committee on Drug Dependence. (2012). Gamma-hydroxybutyric acid (GHB) – Critical review report, 35th ECDD (2012) Agenda item 4.1. Paper presented at the expert committee on drug dependence – Thirty-fifth meeting, Hammamet.Google Scholar
  21. Feigenbaum, J. J., & Howard, S. G. (1996). Does gamma-hydroxybutyrate inhibit or stimulate central DA release? International Journal of Neuroscience, 88(1–2), 53–69.CrossRefPubMedGoogle Scholar
  22. Ferrara, S. D., Tedeschi, L., Frison, G., & Rossi, A. (1995). Fatality due to gamma-hydroxybutyric acid (GHB) and heroin intoxication. Journal of Forensic Science, 40(3), 501–504.CrossRefGoogle Scholar
  23. Fuller, D. E., Hornfeldt, C. S., Kelloway, J. S., Stahl, P. J., & Anderson, T. F. (2004). The Xyrem risk management program. Drug Safety, 27(5), 293–306.CrossRefPubMedGoogle Scholar
  24. Hagenbuch, F. (2011). GBL/GHB – der neue Kick? Das Wichtigste für die Praxis im Überblick. https://www.aerztekammer-bw.de/10aerzte/05kammern/10laekbw/20ehrenamt/30ausschuesse/suchtmedizin/suchtmedizin/gbl-ghb.pdf. Zugegriffen am 15.05.2015.
  25. Hoffmann, M. (2015). Rauschgiftlage 2013 Deutsche Hauptstelle für Suchtfragen (DHS). Lengerich: Pabst Science Publishers.Google Scholar
  26. Hu, R. Q., Banerjee, P. K., & Snead, O. C., 3rd. (2000). Regulation of gamma-aminobutyric acid (GABA) release in cerebral cortex in the gamma-hydroxybutyric acid (GHB) model of absence seizures in rat. Neuropharmacology, 39(3), 427–439.CrossRefPubMedGoogle Scholar
  27. Hunter, A. S., Long, W. J., & Ryrie, C. G. (1971). An evaluation of gamma-hydroxybutyric acid in paediatric practice. British Journal of Anaesthesia, 43(6), 620–628.CrossRefPubMedGoogle Scholar
  28. Johnston, L. D., O’Malley, P. M., Bachman, J. G., & Schulenberg, J. E. (2013). Monitoring the future, national survey results on drug use 1975–2013: Volume 2, college students and adults ages 19–55. Ann Arbor: Institute for Social Research.Google Scholar
  29. Kam, P. C., & Yoong, F. F. (1998). Gamma-hydroxybutyric acid: An emerging recreational drug. Anaesthesia, 53(12), 1195–1198.CrossRefPubMedGoogle Scholar
  30. Kamal, R. M., van Noorden, M. S., Franzek, E., Dijkstra, B. A., Loonen, A. J., & De Jong, C. A. (2016). The neurobiological mechanisms of gamma-hydroxybutyrate dependence and withdrawal and their clinical relevance: A review. Neuropsychobiology, 73(2), 65–80. doi:10.1159/000443173.CrossRefPubMedGoogle Scholar
  31. Keating, G. M. (2014). Sodium oxybate: A review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence. Clinical Drug Investigation, 34(1), 63–80. doi:10.1007/s40261-013-0158-x.CrossRefPubMedGoogle Scholar
  32. Korf, D. J., Nabben, T., Leenders, F., & Benschop, A. (2002). GHB: Tussen Extase en Narcose. Amsterdam: Rozenberg Publishers.Google Scholar
  33. Laborit, H. (1964). Sodium 4-hydroxybutyrate. International Journal of Neuropharmacology, 3, 433–451.CrossRefPubMedGoogle Scholar
  34. Li, J., Stokes, S. A., & Woeckener, A. (1998a). A tale of novel intoxication: A review of the effects of gamma-hydroxybutyric acid with recommendations for management. Annals of Emergency Medicine, 31(6), 729–736.CrossRefGoogle Scholar
  35. Li, J., Stokes, S. A., & Woeckener, A. (1998b). A tale of novel intoxication: Seven cases of gamma-hydroxybutyric acid overdose. Annals of Emergency Medicine, 31(6), 723–728.CrossRefPubMedGoogle Scholar
  36. Marinetti, L., & Montgomery, M. A. (2010). The use of GHB to facilitate sexual assault. Forensic Science Review, 22(1), 41–59.Google Scholar
  37. Miro, O., Nogue, S., Espinosa, G., To-Figueras, J., & Sanchez, M. (2002). Trends in illicit drug emergencies: The emerging role of gamma-hydroxybutyrate. Journal of Toxicology, Clinical Toxicology, 40(2), 129–135.CrossRefPubMedGoogle Scholar
  38. Moncini, M., Masini, E., Gambassi, F., & Mannaioni, P. F. (2000). Gamma-hydroxybutyric acid and alcohol-related syndromes. Alcohol, 20(3), 285–291.CrossRefPubMedGoogle Scholar
  39. No authors listed. (2002). A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep, 25(1), 42–49Google Scholar
  40. Office of National Drug Control Policy (Producer). (2002). Drug policy information clearinghouse fact sheet: Gamma hydroxybutyrate (GHB). http://www.whitehousedrugpolicy.gov/publications/factsht/gamma/. Zugegriffen am 15.11.2005.
  41. Perez, E., Chu, J., & Bania, T. (2006). Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal. Annals of Emergency Medicine, 48(2), 219–220. doi:10.1016/j.annemergmed.2006.03.040.CrossRefPubMedGoogle Scholar
  42. Poldrugo, F., Barker, S., Basa, M., Mallardi, F., & Snead, O. C. (1985). Ethanol potentiates the toxic effects of 1,4-butanediol. Alcoholism, Clinical and Experimental Research, 9(6), 493–497.CrossRefPubMedGoogle Scholar
  43. Rifat, C. (1985). Gamma-OH (Gamma-Hydroxybutyrate): The first authentic antidepressant. http://www.shaman-australis.com/~claude/gamma_oh1.html. Zugegriffen am 15.05.2015.
  44. Robinson, D. M., & Keating, G. M. (2007). Sodium oxybate: A review of its use in the management of narcolepsy. CNS Drugs, 21(4), 337–354.CrossRefPubMedGoogle Scholar
  45. Roth, R. H., & Giarman, N. J. (1965). Preliminary report on the metabolism of gamma-butyrolactone and gamma-hydroxybutyric acid. Biochemical Pharmacology, 14, 177–178.CrossRefPubMedGoogle Scholar
  46. Roth, R. H., & Giarman, N. J. (1968). Evidence that central nervous system depression by 1,4-butanediol in mediated through a metabolite, gamma-hydroxybutyrate. Biochemical Pharmacology, 17(5), 735–739.CrossRefPubMedGoogle Scholar
  47. Saytzeff, A. (1874). Über die Reduction des Succinylchlorids. Liebigs Annalen der Chemie, 171, 258–290.CrossRefGoogle Scholar
  48. Sivilotti, M. L., Burns, M. J., Aaron, C. K., & Greenberg, M. J. (2001). Pentobarbital for severe gamma-butyrolactone withdrawal. Annals of Emergency Medicine, 38(6), 660–665. doi:10.1067/mem.2001.119454.Google Scholar
  49. Snead, O. C., 3rd. (2000). Evidence for a G protein-coupled gamma-hydroxybutyric acid receptor. Journal of Neurochemistry, 75(5), 1986–1996.CrossRefPubMedGoogle Scholar
  50. Snead, O. C., 3rd, & Gibson, K. M. (2005). Gamma-hydroxybutyric acid. New England Journal of Medicine, 352(26), 2721–2732. doi:10.1056/NEJMra044047.CrossRefPubMedGoogle Scholar
  51. Sumnall, H. R., Woolfall, K., Edwards, S., Cole, J. C., & Beynon, C. M. (2008). Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB). Drug and Alcohol Dependence, 92(1–3), 286–290. doi:10.1016/j.drugalcdep.2007.07.009.CrossRefPubMedGoogle Scholar
  52. Takahara, J., Yunoki, S., Yakushiji, W., Yamauchi, J., & Yamane, Y. (1977). Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. Journal of Clinical Endocrinology and Metabolism, 44(5), 1014–1017. doi:10.1210/jcem-44-5-1014.CrossRefPubMedGoogle Scholar
  53. Teter, C. J., & Guthrie, S. K. (2001). A comprehensive review of MDMA and GHB: Two common club drugs. Pharmacotherapy, 21(12), 1486–1513.CrossRefPubMedGoogle Scholar
  54. Thai, D., Dyer, J. E., Jacob, P., & Haller, C. A. (2007). Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clinical Pharmacology and Therapeutics, 81(2), 178–184. doi:10.1038/sj.clpt.6100037.CrossRefPubMedGoogle Scholar
  55. Tunnicliff, G. (1997). Sites of action of gamma-hydroxybutyrate (GHB) – A neuroactive drug with abuse potential. Journal of Toxicology, Clinical Toxicology, 35(6), 581–590.CrossRefPubMedGoogle Scholar
  56. U. S. Xyrem Multicenter Study Group. (2004). Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Medicine, 5(2), 119–123. doi:10.1016/j.sleep.2003.11.002.CrossRefGoogle Scholar
  57. van Amsterdam, J. G., van Laar, M., Brunt, T. M., & van den Brink, W. (2012). Risk assessment of gamma-hydroxybutyric acid (GHB) in the Netherlands. Regulatory Toxicology and Pharmacology, 63(1), 55–63. doi:10.1016/j.yrtph.2012.03.005.CrossRefPubMedGoogle Scholar
  58. Van Cauter, E., Plat, L., Scharf, M. B., Leproult, R., Cespedes, S., L’Hermite-Baleriaux, M., et al. (1997). Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young Men. Journal of Clinical Investigation, 100(3), 745–753. doi:10.1172/JCI119587.CrossRefPubMedPubMedCentralGoogle Scholar
  59. van Noorden, M. S., Kamal, R. M., Dijkstra, B. A., Mauritz, R., & de Jong, C. A. (2015). A case series of pharmaceutical gamma-hydroxybutyrate in 3 patients with severe benzodiazepine-resistant gamma-hydroxybutyrate withdrawal in the hospital. Psychosomatics, 56(4), 404–409. doi:10.1016/j.psym.2014.03.002.CrossRefPubMedGoogle Scholar
  60. Van Sassenbroeck, D. K., De Neve, N., De Paepe, P., Belpaire, F. M., Verstraete, A. G., Calle, P. A., et al. (2007). Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: A case series. Clinical Toxicology (Philadelphia, Pa.), 45(5), 533–538. doi:10.1080/15563650701365818.CrossRefGoogle Scholar
  61. Williams, S. R. (1998). Gamma-hydroxybutyric acid poisoning. Western Journal of Medicine, 168(3), 187–188.PubMedPubMedCentralGoogle Scholar
  62. Wood, D. M., Warren-Gash, C., Ashraf, T., Greene, S. L., Shather, Z., Trivedy, C., & Dargan, P. I. (2008). Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD). QJM, 101(1), 23–29. doi:10.1093/qjmed/hcm117.Google Scholar
  63. Zvosec, D. L., & Smith, S. W. (2003). Unsupported „Efficacy“ claims of gamma hydroxybutyrate (GHB). Academic Emergency Medicine, 10(1), 95–96; author reply 96.CrossRefPubMedGoogle Scholar
  64. Zvosec, D. L., Smith, S. W., Porrata, T., Strobl, A. Q., & Dyer, J. E. (2011). Case series of 226 gamma-hydroxybutyrate-associated deaths: lethal toxicity and trauma. American Journal of Emergency Medicine, 29(3), 319–332. doi:10.1016/j.ajem.2009.11.008.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland 2016

Authors and Affiliations

  1. 1.Department of Psychiatry and Psychotherapy, Campus Charité MitteCharité Universitätsmedizin BerlinBerlinDeutschland
  2. 2.Department of Psychiatry and PsychotherapyCampus Charité MitteBerlinDeutschland

Personalised recommendations